

# ForPatients

by Roche

Multiple Sclerosis (MS)

## A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

**Trial Status**

Active, not recruiting

**Trial Runs In**

1 Countries

**Trial Identifier**

NCT07008378 GN45773

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).

**Genentech, Inc.**

Sponsor

**Phase 1**

Phase

---

**NCT07008378 GN45773**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=18 Years & <= 60 Years

**Healthy Volunteers**

No

---